Gaining Ground: UroGen Pharma Ltd (URGN) Closes Lower at 15.47, Down -8.30

Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The price of UroGen Pharma Ltd (NASDAQ: URGN) closed at $15.47 in the last session, down -8.30% from day before closing price of $16.87. In other words, the price has decreased by -$8.30 from its previous closing price. On the day, 1.73 million shares were traded. URGN stock price reached its highest trading level at $16.85 during the session, while it also had its lowest trading level at $15.08.

Ratios:

We take a closer look at URGN’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 7.20 and its Current Ratio is at 7.47.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Jefferies on February 08, 2023, Downgraded its rating to Hold and sets its target price to $10 from $35 previously.

On April 27, 2022, Berenberg started tracking the stock assigning a Buy rating and target price of $20.

H.C. Wainwright reiterated its Buy rating for the stock on April 16, 2020, while the target price for the stock was revised from $53 to $57.

Insider Transactions:

An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jun 10 ’24 when Schoenberg Mark sold 5,153 shares for $13.08 per share. The transaction valued at 67,401 led to the insider holds 144,284 shares of the business.

Schoenberg Mark sold 12,000 shares of URGN for $168,600 on Mar 18 ’24. The Chief Medical Officer now owns 139,437 shares after completing the transaction at $14.05 per share. On Jan 31 ’24, another insider, Smith Jason Drew, who serves as the General Counsel of the company, sold 4,993 shares for $15.74 each. As a result, the insider received 78,590 and left with 18,824 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, URGN now has a Market Capitalization of 609514944 and an Enterprise Value of 493893984. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.63. Its current Enterprise Value per Revenue stands at 5.859 whereas that against EBITDA is -7.208.

Stock Price History:

The Beta on a monthly basis for URGN is 1.13, which has changed by 0.34991276 over the last 52 weeks, in comparison to a change of 0.2586832 over the same period for the S&P500. Over the past 52 weeks, URGN has reached a high of $24.13, while it has fallen to a 52-week low of $8.69. The 50-Day Moving Average of the stock is 11.00%, while the 200-Day Moving Average is calculated to be 6.09%.

Shares Statistics:

According to the various share statistics, URGN traded on average about 557.26K shares per day over the past 3-months and 1877790 shares per day over the past 10 days. A total of 32.49M shares are outstanding, with a floating share count of 30.77M. Insiders hold about 14.84% of the company’s shares, while institutions hold 83.31% stake in the company. Shares short for URGN as of 1715731200 were 4467506 with a Short Ratio of 9.43, compared to 1713139200 on 4198943. Therefore, it implies a Short% of Shares Outstanding of 4467506 and a Short% of Float of 12.82.

Most Popular